Preclinical News and Research

RSS

Recent advancements in the development of models to study primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is a rare non-communicable disorder that affects the liver. Chronic inflammation in and around the bile duct is followed by the development of fibrotic obstructions within the duct, causing bile to accumulate within the liver.

19 May 2026

How antibody-drug conjugates are redefining targeted cancer therapy

Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but their success depends on better targets, payloads, linkers, dosing, and patient selection. The Cell review shows that next-generation ADCs could widen treatment options, but safety, resistance, tumor heterogeneity, and clinical translation remain major barriers.

19 May 2026

UCLA researchers identify potential drug target for treating Fragile X syndrome

UCLA Health researchers have identified a potential drug target for treating Fragile X syndrome, the most common genetic cause of intellectual disability and autism that affects roughly 1 in 2,000 boys.

18 May 2026

DNA-guided CRISPR system targets RNA and expands Cas12 beyond gene editing

Researchers developed ΨDNA, a DNA-based CRISPR guide that allows Cas12 enzymes to target RNA with high specificity while retaining compatibility with DNA-editing workflows. The platform detected HCV RNA in clinical samples and enabled programmable RNA knockdown, multiplex targeting, and RNA modification in human cells.

18 May 2026

New therapies could help type 1 diabetes care move beyond insulin alone

Disease-modifying therapies for type 1 diabetes are beginning to move care beyond insulin replacement by targeting immune dysregulation, beta-cell stress, and preservation of endogenous beta-cell function. Teplizumab marks a major clinical milestone, but the review emphasizes that durable metabolic remission will likely require earlier screening, better patient selection, and sequential or combination therapies.

18 May 2026

Preclinical models map genetic changes behind multiple sclerosis nerve damage

More than 1 million people across the United States live with multiple sclerosis (MS), a disease that affects the brain, optic nerves and spine.

18 May 2026

Blood metabolite patterns could reveal dementia risk in midlife

Research shows that blood metabolite profiles can indicate dementia risk, offering a potential tool for early detection and prevention of cognitive decline.

18 May 2026

Olive waste extract may help lower fat and improve muscle markers

A polyphenol-rich olive oil byproduct may enhance muscle health, reducing fat mass and improving antioxidant markers in adults with metabolic risk factors.

18 May 2026

Aged immune cells may drive memory decline by releasing a brain-aging protein

A preclinical mouse study in Immunity suggests that aged circulating CD8+ T cells can disrupt hippocampal function and impair learning and memory. The findings point to granzyme K, a secreted factor linked to age-associated CD8+ T cells, as a potential target for restoring aspects of cognition in aging.

17 May 2026

Multi-institutional trial explores new lifeline for advanced prostate patients

For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are limited – and time matters. As the disease progresses, the window for effective, less intensive treatments begins to close.

15 May 2026

Psilocybin offers fast-acting alternative to traditional antidepressants

A single dose of the psychedelic substance psilocybin can provide rapid relief from depressive symptoms – within just a few days. This is shown by the first randomised, double-blind study in Sweden of psilocybin for depression. The effect persisted for over three months, according to researchers at Karolinska Institutet.

15 May 2026

Study reveals why aging makes the body more vulnerable to breast cancer

Researchers at Georgetown's Lombardi Comprehensive Cancer Center have identified a mechanism that may help explain a key reason why older people experience worse outcomes from breast cancer.

15 May 2026

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

ExiVex Biopharma (formerly EmerRx Biopharma), a clinical-stage pharmaceutical company developing a proprietary dual-chamber intranasal drug delivery platform, today announced in-human pharmacokinetic (PK) data for its lead candidate EMRX-101, an intranasal naloxone product targeting opioid-induced respiratory depression.

From Hanson Wade Group - 4th Nasal Formulation & Delivery Summit 15 May 2026

Thyroid hormone profiles provide critical prognostic clues for patients facing liver failure

Early and accurate prognostic assessment is crucial to prevent disease progression in liver failure. Thyroid hormones (THs), particularly triiodothyronine (T3), are key metabolic regulators and play an important role in liver regeneration. Liver failure is frequently complicated by non‑thyroidal illness syndrome (NTIS), characterized by low T3 with normal or slightly elevated TSH and T4.

14 May 2026

Base editing approach repairs deadly Dravet syndrome mutation in mice

Gene editing can repair a DNA error in mice that causes Dravet syndrome, a rare, incurable, and potentially deadly form of childhood epilepsy. After the edit, the mice have far fewer seizures and live much longer.

13 May 2026

Next-generation cancer therapy shows early promise as treatment candidate for glioblastoma

A next-generation cancer therapy being developed at McMaster University has shown early promise as a treatment candidate for glioblastoma, the most aggressive and most common type of primary brain cancer in adults.

13 May 2026

Immune-regulating molecule may offer new treatment approach for IBD patients

Mayo Clinic researchers have identified an immune-regulating molecule that may help explain why some patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, do not respond to commonly used therapies.

13 May 2026

New gene editing approach improves survival in epileptic mice

In a world first, a research team at the University of Zurich has successfully treated mice carrying an inherited form of epilepsy.

13 May 2026

Icing injuries may delay healing and prolong pain recovery

Icing a sprained ankle or sore muscle, long used to reduce pain and swelling, may in the longer run delay recovery and prolong pain, new research suggests.

13 May 2026

Researchers find new way to deliver drugs directly into cancer cells

National University of Singapore Researchers at the National University of Singapore (NUS) have developed a high-throughput method to identify gold nanoparticles capable of delivering therapies directly to mitochondria (the energy centres inside cancer cells).

13 May 2026